GE HealthCare Emphasizes New Advances in Breast Ultrasound
The AI tools for the newly launched Invenia ABUS Prime ultrasound platform reportedly facilitate a 40 percent increase in scan speed and up to a 93 percent sensitivity rate for lesion detection in women with dense breasts.
Emphasizing a combination of enhanced breast cancer detection, improved efficiency and greater access to ultrasound imaging, GE HealthCare announced the launch of the Invenia ABUS Prime device and the recently FDA-cleared ABUS StreamVue ultrasound software.
Geared to supplemental screening for women with dense breasts, the
• up to a 40 percent increase in scan speed;
• a cSound™ Imageformer with AI-powered tools that facilitate improved consistency in scan quality; and
• other AI advances that have demonstrated a 33 percent decrease in reading time and up to a 93 percent sensitivity for breast lesion detection.
“Invenia ABUS Prime builds on our commitment to advancing supplemental breast screening for women with dense breasts,” said Karley Yoder, the CEO of Ultrasound Solutions and Advanced Imaging Solutions at GE HealthCare. “As breast imaging networks look to scale across sites, Invenia ABUS Prime can help deliver streamlined workflows, reproducible imaging, with features designed to support both patient comfort and clinician efficiency.”
GE HealtthCare added that the ABUS StreamVue software facilitates streamlined installation across enterprise imaging environments, and bolsters access for those in remote reading settings.
Related Content
